Cellectar Biosciences to submit for European approval in 3Q 2026.
ByAinvest
Friday, Jan 9, 2026 8:11 am ET1min read
CLRB--
• Cellectar Biosciences to submit Iopofosine I 131 for EU approval in 3Q 2026 • Plans to present WM patients' final results and subset analysis from Phase 2 CLOVER WaM study • Expects to dose first patients in Phase 1b CLR 125 study for TNBC in 1Q26, with interim data mid-2026 • Company to highlight 2026 strategic initiatives at Biotech Showcase in San Francisco
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet